A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.
about
Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosisBiomarkers of Alzheimer's diseaseProteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosisA Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesisVGF changes during the estrous cycle: a novel endocrine role for TLQP peptides?Exploring Biomarkers for Alzheimer's DiseaseOpportunities and limitations of SELDI-TOF-MS in biomedical research: practical advicesGenotype and plasma concentration of cystatin C in patients with late-onset Alzheimer diseasePeptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkersHigh Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidMultiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosisIdentification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's diseaseMass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches.Use of proteomic analysis to monitor responses to biological therapies.Top-down identification of endogenous peptides up to 9 kDa in cerebrospinal fluid and brain tissue by nanoelectrospray quadrupole time-of-flight tandem mass spectrometry.MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer.Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model.Proteomic study of plasma proteins in pregnant women with asthma.Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid.Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry to identify patients with chronic obstructive pulmonary disease.Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations.Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations.A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.Approaching clinical proteomics: current state and future fields of application in fluid proteomics.Proteomics Discovery of Disease Biomarkers.Assessment of Protein Stability in Cerebrospinal Fluid Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Protein Profiling.DNA methylation-based forensic age prediction using artificial neural networks and next generation sequencingComparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.Application of "omics" to prion biomarker discovery.Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment.Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients.Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENTIdentification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry.Serum peptidome profiling in patients with gastric cancer.
P2860
Q21144689-EFB3DAE0-D7AC-4F48-89C2-C516F3E93BF4Q24650667-7491861D-B629-46B8-B4FB-41C3E36C84E3Q24678722-930DB784-A5F9-4C86-8A25-70610B1ADE08Q25256334-AB1F1F11-3203-4E49-8B80-F6915033FFE6Q27315300-266BA866-6ADF-4135-8A1C-05D54EBE3FCFQ27343928-F2054EE8-EA93-488D-AC2A-F6BB941F9CE3Q28079218-4FDB3C87-DE60-4F7C-9A9F-8B95F2097C9EQ28287384-EF6BED6D-3014-40BF-B1AA-7AD8EFAFE97DQ28289057-435908C8-41E0-4C70-8681-F0F2076A16A7Q28477629-42728457-69DF-455F-863A-44199045317EQ28547231-C9FC220B-7193-4376-8C2A-A9A6F0E97F14Q28740917-36AA6114-842D-42C7-B5D2-7F3B20AEFCF4Q28743561-FBE53E2E-0F39-4CD6-9929-4089C9233710Q30751781-05A4D165-529C-43EA-9728-EE28E38361B5Q31153391-6FB43DE8-E1DA-412F-BE86-17252FFD9588Q33196034-257A89E7-2991-4106-A6FC-C62B35AE53A5Q33211791-A2DE4D30-2605-4D27-AB04-B5A7D7D44E5DQ33217610-43D074A6-9C24-4BCC-8A0A-567E3EA14E49Q33217936-FD08E905-826E-41C6-B733-28A5245AC11DQ33232064-236A9120-68A4-444B-B506-CFEBE808CD6BQ33237201-F0C9019B-4FE9-4B6A-A51A-DDE9CABB42E1Q33241392-503076D9-817B-4757-A8CB-DDC98EEEA53DQ33266904-15A0F64D-49E4-4E36-A31C-106EBDA269DDQ33282300-56FC9BE7-44DC-474B-A9B8-D0146525FFB8Q33304365-E17FE8A3-25A5-4456-85DF-D9B0098C680BQ33304417-CE57D4D0-6EA6-406F-A343-0C288F6E8882Q33467523-6CE3C5AD-74BF-43D7-AA51-2B8BA925CAF0Q33478412-8D2B9B6F-4A62-470B-A4BE-8FA860D26B3BQ33536646-635CC4E7-3333-4A6B-8A28-1E373E658819Q33567569-B3F017EE-03CE-41DC-952D-642323FD170EQ33691896-C2D15E5A-B539-4FE7-92F8-4045208FB342Q33708360-8DD8A079-F2DA-4291-BEEC-90FCD0B9D3D2Q33736582-1F1D35FD-5985-486E-A776-25E85D6F73BEQ33745920-4B126CEE-8227-4586-BBE8-9967C5AE7B7BQ33753194-FAB3473B-FCDD-44F4-810D-9EE733994B06Q33764466-C4D2D5DF-F47C-4F6F-891C-ED3772C136B8Q33769278-56382EB3-AADF-49C1-BEC9-A3487485A955Q33818120-3CE66DA5-2BB0-4B99-93C2-C9C5E406A42BQ33856292-B5D2A30C-DA9D-4A1C-8C24-274441C5D421Q33955495-3F56F828-1575-4CBC-BF9A-77CE908E7A5F
P2860
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@ast
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@en
type
label
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@ast
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@en
prefLabel
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@ast
A panel of cerebrospinal fluid ...... gnosis of Alzheimer's disease.
@en
P2093
P921
P356
P1433
P1476
A panel of cerebrospinal fluid ...... agnosis of Alzheimer's disease
@en
P2093
Alexander Scherl
Denis F Hochstrasser
Isabelle Demalte
Jean-Charles Sanchez
Odile Carrette
Oezkarn Yalkinoglu
Pierre Burkhard
P304
P356
10.1002/PMIC.200300470
P577
2003-08-01T00:00:00Z